Mega Genomics Limited disclosed that it repurchased 92,000 ordinary shares on 21 September 2026 via on-market transactions at prices ranging from HK$7.005 to HK$7.01 per share. The buyback cost totalled HK$0.64 million, translating to a volume-weighted average price of HK$7.01.

Following the transaction, issued shares outstanding (excluding treasury shares) fell by 0.0413% to 222.80 million, while treasury shares rose to 1.51 million. The total issued share count, inclusive of treasury stock, remains unchanged at 224.30 million.

Since the current repurchase mandate was approved on 21 May 2026, the company has repurchased 1.51 million shares—0.67% of the issued share base on the mandate date—against an authorisation to buy back up to 22.43 million shares.

In line with Hong Kong Listing Rule 10.06(3)(a), Mega Genomics is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, effective until 21 October 2026.